

## STANDARD TREATMENT WORKFLOW (STW)

# Eczema/Dermatitis

Binod K Khaitan<sup>1</sup>, Deepika Pandhi<sup>2</sup>, Ananta Khurana<sup>3</sup>, Dipankar De<sup>4</sup>, Rahul Mahajan<sup>5</sup>, Renu George<sup>6</sup>, Vishal Gupta<sup>7</sup>

<sup>1</sup>All India Institute of Medical Sciences, New Delhi; <sup>2</sup>University College of Medical Sciences, New Delhi; <sup>3</sup>Dr. Ram Manohar Lohia Hospital, New Delhi; <sup>4</sup>Postgraduate Institute of Medical Education and Research, Chandigarh; <sup>5</sup>Postgraduate Institute of Medical Education and Research, Chandigarh; <sup>6</sup> Christian Medical College, Vellore; <sup>7</sup>All India Institute of Medical Sciences, New Delhi

### CORRESPONDING AUTHOR

Dr Binod K Khaitan, Department of Dermatology, All India Institute of Medical Sciences, New Delhi  
Email: [binodkhaitan@hotmail.com](mailto:binodkhaitan@hotmail.com)

### CITATION

Khaitan BK, Pandhi D, Khurana A, De D, Mahajan R, George R, Gupta V. Eczema/Dermatitis. Journal of the Epidemiology Foundation of India. 2024;2(1Suppl):S89-S90.

DOI: <https://doi.org/10.56450/JEFI.2024.v2i1Suppl.045>


*This work is licensed under a Creative Commons Attribution 4.0 International License.*

*@The Author(s). 2024 Open Access*

### DISCLAIMER





This article/STW, was originally published by Indian Council of Medical Research (ICMR) under Standard Treatment Workflow. The reprinting of this article in Journal of the Epidemiology Foundation of India (JEFI) is done with the permission of ICMR. The content of this article is presented as it was published, with no modifications or alterations. The views and opinions expressed in the article are those of the authors and do not necessarily reflect the official policy or position of JEFI or its editorial board. This initiative of JEFI to reprint STW is to disseminate these workflows among Health Care Professionals for wider adoption and guiding path for Patient Care.

July/2022



|   | MAJOR FORMS OF ECZEMA  |   |
|---|--|---|
| <b>ACUTE</b><br>Red, edematous plaques with small, grouped vesicles | <b>EXOGENOUS ECZEMAS</b><br>Those with a known exogenous trigger, management of exogenous eczemas is to remove the cause if possible, along with pharmacological intervention <ul style="list-style-type: none"><li>• Allergic contact eczema</li><li>• Dermatophytide</li><li>• Eczematous polymorphic light eruption</li><li>• Infective eczema</li><li>• Irritant contact eczema</li><li>• Photoallergic contact eczema</li><li>• Post-traumatic eczema</li></ul> | <b>ENDOGENOUS ECZEMAS</b><br>Without a known exogenous trigger, more often requires pharmacological intervention <ul style="list-style-type: none"><li>• Asteatotic eczema</li><li>• Atopic eczema</li><li>• Chronic superficial scaly eczema</li><li>• Eyelid eczema</li><li>• Hand eczema</li><li>• Juvenile plantar dermatosis</li><li>• Nummular eczema</li><li>• Pityriasis alba</li><li>• Eczema associated with systemic disease</li><li>• Seborrheic eczema</li><li>• Venous eczema</li></ul> |
| <b>SUBACUTE</b><br>Erythematous plaques with scaling or crusting    |  |   |
| <b>CHRONIC</b><br>Lesions may have scaling or lichenification       |  |   |

**Standard Treatment Workflow (STW)  
ECZEMA/ DERMATITIS  
ICD-10-L20**

|   |   |   |
|---|---|---|
| <p><b>ACUTE</b><br/>Red, edematous plaques with small, grouped vesicles</p>   | <b>MAJOR FORMS OF ECZEMA</b>  |   |
| <p><b>SUBACUTE</b><br/>Erythematous plaques with scaling or crusting</p>  | <p><b>EXOGENOUS ECZEMAS</b><br/>Those with a known exogenous trigger, management of exogenous eczemas is to remove the cause if possible, along with pharmacological intervention</p> <ul style="list-style-type: none"> <li>• Allergic contact eczema</li> <li>• Dermatophytide</li> <li>• Eczematous polymorphic light eruption</li> <li>• Infective eczema</li> <li>• Irritant contact eczema</li> <li>• Photoallergic contact eczema</li> <li>• Post-traumatic eczema</li> </ul>  | <p><b>ENDOGENOUS ECZEMAS</b><br/>Without a known exogenous trigger, more often requires pharmacological intervention</p> <ul style="list-style-type: none"> <li>• Asteatotic eczema</li> <li>• Atopic eczema</li> <li>• Chronic superficial scaly eczema</li> <li>• Eyelid eczema</li> <li>• Hand eczema</li> <li>• Juvenile plantar dermatosis</li> <li>• Nummular eczema</li> <li>• Pityriasis alba</li> <li>• Eczema associated with systemic disease</li> <li>• Seborrhoeic eczema</li> <li>• Venous eczema</li> </ul>                |
| <p><b>CHRONIC</b><br/>Lesions may have scaling or lichenification</p>   | <b>HISTORY</b>  |   |
| <ul style="list-style-type: none"> <li>• Associated history of atopy, allergic rhinitis or asthma in patient and family members</li> <li>• Age of onset is usually early( less than 5 years) in atopic dermatitis</li> <li>• Site of onset- predominant flexural involvement in atopic dermatitis</li> <li>• Possible allergens implicated</li> <li>• High risk occupations with increased exposure to allergens or irritants such as agricultural work, masons, hair-dressers etc.</li> <li>• Associated photosensitivity, especially in parthenium dermatitis</li> <li>• Change in severity with season; summer exacerbation in parthenium dermatitis</li> <li>• Winter exacerbation in atopic dermatitis</li> </ul>  |   |   |
| <b>EXAMINATION</b>  |   |   |
| <p><b>ATOPIC DERMATITIS</b></p> <ul style="list-style-type: none"> <li>• <b>Infantile:</b> Most commonly on the face, followed by involvement of extensors of the knees and elbows</li> <li>• <b>Childhood/ Adult phase:</b> Pattern changes to flexural involvement (cubital and popliteal fossa)</li> </ul>  <p style="text-align: center; font-weight: bold;">ATOPIC DERMATITIS</p>   | <p><b>ENDOGENOUS ECZEMA</b></p> <ul style="list-style-type: none"> <li>• <b>Nummular dermatitis/eczematous:</b> Circular or oval, commonly affecting neck, hands and feet</li> <li>• <b>Seborrhoeic dermatitis:</b> Involvement of the scalp and other seborrhoeic areas and skin folds; ranging from mild flaking to thicker, yellow, greasy scales and crusts</li> <li>• <b>Venous eczema:</b> Eczema affecting the medial aspect of ankles associated with varicose veins/ venous incompetence</li> </ul>   | <p><b>CONTACT DERMATITIS</b></p> <ul style="list-style-type: none"> <li>• It can be irritant or allergic</li> <li>• Eczema pattern corresponds to the pattern of allergen/ irritant exposure</li> <li>• It can be localized or widespread</li> </ul> <p><b>EXAMPLE:</b> Parthenium dermatitis contact dermatitis to nickel contact dermatitis to hair dye</p>   |
| <b>DIAGNOSIS</b>  |   |   |
| <ul style="list-style-type: none"> <li>• Most cases of eczema can be diagnosed clinically</li> <li>• Secondary infection is common, may cause eczema to flare and can be confirmed by taking swabs for culture and sensitivity</li> <li>• Patch tests are designed to detect allergens in cases of suspected allergic contact dermatitis</li> <li>• Potassium hydroxide (KOH) preparation or biopsy when dermatophyte infection or other diagnoses are suspected</li> </ul>   |   |   |
| <b>DIFFERENTIAL DIAGNOSIS</b>   |   |   |
| <ul style="list-style-type: none"> <li>• Tinea corporis</li> <li>• Psoriasis</li> <li>• Cutaneous t-cell lymphoma (CTCL)</li> </ul>   |   |   |
| <b>TREATMENT</b>  |   |   |
| <p><b>GENERAL PRINCIPLES</b></p> <ul style="list-style-type: none"> <li>• Avoidance of allergens and irritant materials</li> <li>• Daily bath with mild soap, keep nails short, avoid scratching</li> <li>• Moisturizer are cornerstone in the management of eczema; to be applied immediately after bathing while the skin is still damp and apply multiple times during the day</li> <li>• Antihistamines for (eg. levocetirizine) for control of pruritus</li> <li>• Topical corticosteroids (TCS) mild – Over face/ flexures genitals. Mid potent TCS over palms, soles and lichenified lesions</li> <li>• Topical calcineurin inhibitors (TCIs)- Face/ flexures genitals and/or as maintenance treatment</li> <li>• If secondary infection (pain, pus discharge, yellow crust)- Treat with topical/ oral antibiotic as needed</li> </ul> | <p><b>SPECIFIC MANAGEMENT</b></p> <p><b>Primary/Secondary Level</b></p> <ul style="list-style-type: none"> <li>• Treatment of active eczema: Daily use of TCS of appropriate strength until completely clear ± antihistamine (for sedative/antipruritic effects) ± oral antibiotic course (if superinfection) - (refer to STW on rational use of topical therapy)</li> <li>• Maintenance treatment for area where lesions are more resistant to treatment or there is propensity for relapse, like flexural skin- Intermittent use of mid-potency TCS (e.g. 2-3 days/week) and/or TCI (e.g. 3-5 days/week)</li> </ul> <p><b>Tertiary Level</b></p> <ul style="list-style-type: none"> <li>• Severe disease in addition to above may require phototherapy or systemic treatment (Short course of oral corticosteroids, cyclosporine, azathioprine etc.)</li> </ul> |   |
| <p>👉 <b>AVOIDANCE OF PROVOKING AGENTS, MOISTURIZERS AND EARLY TREATMENT ARE THE AIM OF ECZEMA MANAGEMENT</b></p>  |   |   |
| <p>This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of DHR for more information: <a href="http://stw.icmr.org.in">stw.icmr.org.in</a> for more information.</p> <p>©Department of Health Research, Ministry of Health &amp; Family Welfare, Government of India.</p>   |   |   |